BiotechTube

OROS Methylphenidate

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Attention Deficit Disorder With Hyperactivity

Conditions

Attention Deficit Disorder With Hyperactivity

Trial Timeline

Mar 1, 2008 → Jun 1, 2008

NCT ID
NCT00758160

About OROS Methylphenidate

OROS Methylphenidate is a approved stage product being developed by Johnson & Johnson for Attention Deficit Disorder With Hyperactivity. The current trial status is completed. This product is registered under clinical trial identifier NCT00758160. Target conditions include Attention Deficit Disorder With Hyperactivity.

What happened to similar drugs?

11 of 20 similar drugs in Attention Deficit Disorder With Hyperactivity were approved

Approved (11) Terminated (1) Active (9)
✅atomoxetineEli LillyApproved
✅AtomoxetineEli LillyApproved
✅Atomoxetine HydrochlorideEli LillyApproved
🔄AtomoxetineEli LillyPhase 3
✅AtomoxetineEli LillyApproved
✅Atomoxetine hydrochloride + PlaceboEli LillyApproved
🔄CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00758160ApprovedCompleted

Competing Products

20 competing products in Attention Deficit Disorder With Hyperactivity

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
39
Atomoxetine + PlaceboEli LillyPhase 2/3
38
AtomoxetineEli LillyApproved
35
Atomoxetine HydrochlorideEli LillyApproved
43
AtomoxetineEli LillyPhase 3
40
AtomoxetineEli LillyApproved
43
Atomoxetine hydrochloride + PlaceboEli LillyApproved
43
CLONICEL (Clonidine HCl sustained release)ShionogiPhase 3
40
Donepezil hydrochloride + PlaceboEisaiPhase 3
40
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
38
Atomoxetine + PlaceboEli LillyApproved
43
AtomoxetineEli LillyApproved
43
AtomoxetineEli LillyPre-clinical
26
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine hydrochlorideEli LillyPhase 3
40
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
43
atomoxetineEli LillyPhase 3
40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
40
Atomoxetine HydrochlorideEli LillyApproved
43
Atomoxetine HydrochlorideEli LillyPhase 3
40